Recombinant antivenoms based on mixtures of human antibodies against D. jamesoni toxins

Urska Pus; Robert Harrison; Mikael Rørdam Andersen; Nicholas Casewell; Andreas Hougaard Laustsen

Recombinant antivenoms based on mixtures of human antibodies against D. jamesoni toxins

Urska Pus, Robert Harrison, Mikael Rørdam Andersen, Nicholas Casewell, Andreas Hougaard Laustsen

Research output: Contribution to conference › Poster › Research › peer-review

114 Downloads (Orbit)

Abstract

Each year, more than 5 million people worldwide are affected by a snakebite, resulting in 150,000 deaths, and 400,000 amputations. The current medical treatment against envenoming is based on the administration of an animal-derived antiserum, containing antibodies against snake venom toxins. Due to the heterologous and immunogenic nature of antivenom, patients in up to 80% of the cases experience serum sickness and anaphylaxis, which in some cases leads to death.

Original language	English
Publication date	2016
Number of pages	1
Publication status	Published - 2016
Event	Symposium for Biological and Life Science Students 2016 - Cambridge, United Kingdom Duration: 25 Nov 2016 → 25 Nov 2016

Conference

Conference	Symposium for Biological and Life Science Students 2016
Country/Territory	United Kingdom
City	Cambridge
Period	25/11/2016 → 25/11/2016

Access to Document

Urska W1Final published version, 970 KB

OpenUrl availability

Full text

Cite this

@conference{7f84531312ce424aad706911830f76cc,

title = "Recombinant antivenoms based on mixtures of human antibodies against D. jamesoni toxins",

abstract = "Each year, more than 5 million people worldwide are affected by a snakebite, resulting in 150,000 deaths, and 400,000 amputations. The current medical treatment against envenoming is based on the administration of an animal-derived antiserum, containing antibodies against snake venom toxins. Due to the heterologous and immunogenic nature of antivenom, patients in up to 80% of the cases experience serum sickness and anaphylaxis, which in some cases leads to death.",

author = "Urska Pus and Robert Harrison and Andersen, {Mikael R{\o}rdam} and Nicholas Casewell and Laustsen, {Andreas Hougaard}",

year = "2016",

language = "English",

note = "Symposium for Biological and Life Science Students 2016, SymBLS ; Conference date: 25-11-2016 Through 25-11-2016",

}

TY - CONF

T1 - Recombinant antivenoms based on mixtures of human antibodies against D. jamesoni toxins

AU - Pus, Urska

AU - Harrison, Robert

AU - Andersen, Mikael Rørdam

AU - Casewell, Nicholas

AU - Laustsen, Andreas Hougaard

PY - 2016

Y1 - 2016

N2 - Each year, more than 5 million people worldwide are affected by a snakebite, resulting in 150,000 deaths, and 400,000 amputations. The current medical treatment against envenoming is based on the administration of an animal-derived antiserum, containing antibodies against snake venom toxins. Due to the heterologous and immunogenic nature of antivenom, patients in up to 80% of the cases experience serum sickness and anaphylaxis, which in some cases leads to death.

AB - Each year, more than 5 million people worldwide are affected by a snakebite, resulting in 150,000 deaths, and 400,000 amputations. The current medical treatment against envenoming is based on the administration of an animal-derived antiserum, containing antibodies against snake venom toxins. Due to the heterologous and immunogenic nature of antivenom, patients in up to 80% of the cases experience serum sickness and anaphylaxis, which in some cases leads to death.

M3 - Poster

T2 - Symposium for Biological and Life Science Students 2016

Y2 - 25 November 2016 through 25 November 2016

ER -

Recombinant antivenoms based on mixtures of human antibodies against D. jamesoni toxins

Abstract

Conference

Access to Document

OpenUrl availability

Fingerprint

Cite this